ArticleThe Journal of experimental medicine1992
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients.
Article in The Journal of experimental medicine, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 156 citations in OpenAlex.
- Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis.Journal of Korean medical science · 2004Trial
- Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL).Clinical and experimental immunology · 1998Trial
- Tofacitinib in Leprosy: A Novel Therapeutic Approach in Chronic Recalcitrant Type II Reactions.Cureus · 2024Article
- Susceptibility and resistance in leprosy: Studies in the mouse model.Immunological reviews · 2021Review
- Intraperitoneal injection of IFN-γ restores microglial autophagy, promotes amyloid-β clearance and improves cognition in APP/PS1 mice.Cell death & disease · 2020Article
- Emerging Concepts of Adaptive Immunity in Leprosy.Frontiers in immunology · 2018Review
- The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.Frontiers in immunology · 2018Article
- Genetic polymorphisms of the IL6 and NOD2 genes are risk factors for inflammatory reactions in leprosy.PLoS neglected tropical diseases · 2017Article
- A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.Frontiers in immunology · 2017Review
- Advances and hurdles on the way toward a leprosy vaccine.Human vaccines · 2011Review
- The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression.Clinical and experimental immunology · 2011Article
- Integrated pathways for neutrophil recruitment and inflammation in leprosy.The Journal of infectious diseases · 2010Article
- Mycobacterium leprae actively modulates the cytokine response in naive human monocytes.Infection and immunity · 2010Article
- Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.Infection and immunity · 2009Article
- Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.Clinical and experimental immunology · 2007Article
- The continuing challenges of leprosy.Clinical microbiology reviews · 2006Review
- Thalidomide Prevents Alcoholic Liver Injury in Rats Through Inhibition of Kupffer Cell Sensitization.Comparative hepatology · 2004Article
- Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha.Immunology · 2003Article
- Immune deficiency presenting as mycobacterial infection.Clinical reviews in allergy & immunology · 2001Review
- Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions.Immunology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
10 patients with borderline and lepromatous leprosy were selected for a prolonged trial with recombinant interferon gamma (rIFN-gamma). Patients received 30 micrograms intradermally for six injections over a 9-d period, and then either 100 micrograms intradermally every 1 mo for 10 mo or every 2 wk for 5 mo (total, 1.2 mg). Erythema nodosum leprosum (ENL) was induced in 60% of the patients within 6-7 mo, as compared with an incidence of 15% per year with multiple drug therapy alone. The mean whole-body reduction in bacterial index over the first 6 mo was 0.9 log units. Cutaneous induration at the intradermal injection sites of greater than or equal to 15 mm predicted the development of a subsequent reactional state. Monocytes obtained from patients receiving the lymphokine demonstrated an increased respiratory burst and a 2.5-5.1-fold increase in tumor necrosis factor alpha (TNF-alpha) secretion in response to agonists. Patients in ENL had an even higher release of TNF-alpha from monocytes as well as high levels of TNF-alpha in the plasma (mean, 2,000 pg/ml). Thalidomide therapy was required to treat the systemic manifestations of ENL. Control of toxic symptoms with thalidomide was associated with a 50-80% reduction in agonist-stimulated monocyte TNF-alpha secretion. IFN-gamma enhanced the monocyte release of TNF-alpha by 3-7.5-fold (agonist dependent) when added to patient's cells in vitro, and this could be suppressed by the in vitro addition of 10 micrograms/ml of thalidomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.